Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All LivaNova PLC filings on SEC EDGAR ↗
LivaNova CFO Alex Shvartsburg Sells $227K of Stock
Alex Shvartsburg, CFO, sold 2,500 shares of LivaNova PLC at $90.91 a share, worth $227K in total on Nov 12, 2026. Shares held after the trade: 42,147 (-5.6%).
LivaNova PLC reported net revenue of $1.15 billion for the nine months ended September 30, 2026, a significant increase from $1.03 billion in the prior year period. The company swung to a net income of $165.2 million compared to a net loss of $273.4 million in 2025, primarily due to the absence of the large SNIA environmental liability expense recorded in the previous year.
LivaNova reported 9.9% revenue growth for the third quarter of 2026, driven by strong demand for its Cardiopulmonary and Epilepsy technologies. The company raised its full-year 2026 constant-currency revenue growth guidance to 9-10% and increased its adjusted diluted EPS outlook. Key operational milestones included the launch of a new oxygenator manufacturing line and the establishment of new CPT codes for its sleep apnea therapy.
Term
Q3 2026
“Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies. We also made meaningful progress against key milestones, positioning us to address significant market demand while expanding patient access to care.”
Vladimir Makatsaria, Chief Executive Officer of LivaNova